Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Atomoxetine Improves Multiple Symptoms in ADHD With Comorbid Anxiety: Presented at AACAP

        By Paula Moyer

        SAN DIEGO, CA -- November 2, 2006 -- Patients with attention deficit/hyperactivity disorder (ADHD) and comorbid anxiety get some relief from both conditions when they are treated with atomoxetine (Strattera), according to investigators speaking here at the 53rd annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP).

        "Atomoxetine was efficacious in treating ADHD symptoms in children and adolescents with these 2 conditions," said principal investigator Daniel Geller, MBBS, researcher, pediatric psychopharmacology research program, Massachusetts General Hospital, Cambridge, Massachusetts. "It did not exacerbate comorbid anxiety."

        Dr. Geller and his co-investigators conducted the study because of their concern that 25% to 50% of patients with ADHD have comorbid anxiety disorders, Dr. Geller said in a presentation on October 26th. Therefore, they conducted a study involving 176 patients with ADHD who also had comorbid anxiety.

        Patients were randomized to receive either atomoxetine or placebo for 12 weeks; for patients on active treatment, the targeted dose was 1.2 mg/kg/day, with increases up to 1.8 mg/kg/day in patients who did not respond to the targeted treatment.

        The treatment measures were the Multidimensional Anxiety Scale for Children (MASC), the Life Participation Scale for ADHD-Revised (LPS-ADHD-R), the Child Health Questionnaire-Parent Completed Full Length (CHQ-PF50), and the Clinical Global Impression-Severity scale (CGI-S).

        Among the original patients, 132 completed the study, 66 in each group. Treated patients had a significantly greater improvement on the MASC, a decrease of 4.6 points, compared with those on placebo, who had a decrease of 2.1 points (P = .009). Similarly, on the LPS-ADHD-R, treated patients had an increase of 9.5 points and those on placebo has an increase of 3.1 points (P = .002). Treated patients also had significantly greater improvements on the CHQ-PF50 Psychosocial subscale, an increase of 6.9 points compared with an increase of 3.3 points in the placebo group (P = .019). And on the CGI-S, treated patients had a decrease of 0.9 points and those on placebo had a decrease of 0.4 points (P = .002).

        Decreased appetite was the only adverse effect experienced by significantly more by treated patients than those on placebo, which occurred in 14.3% of treated patients and in 3.8% of those on placebo (P = .025).

        "The results provide evidence of the effect of atomoxetine in treating anxiety symptoms in this population," the investigators reported. "Patient-reported improvements in anxiety symptoms were consistent with investigator-reported improvements in children with ADHD and comorbid anxiety."

        The study was funded by Eli Lilly and Company, which manufactures Strattera.


        [Presentation title: Atomoxetine Treatment for Pediatric Patients With ADHD and Comorbid Anxiety. Abstract C9]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send